We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High Homocysteine Levels Linked to Alzheimer's

By Biotechdaily staff writers
Posted on 21 May 2002
A new study has found that people with elevated levels of homocysteine in the blood have nearly twice the risk of developing Alzheimer's disease (AD) vs people with normal levels. More...
The findings were reported in the February 14, 2002, issue of The New England Journal of Medicine.

The study was conducted by researchers at Boston University (MA, USA) and Tufts University (also in Boston), based on data on 1,092 dementia-free participants. The participants, whose average age was 76, were enrolled in 1976-78. Their plasma homocysteine levels were measured in 1979-1982 and in 1986-1990. Age, sex, vascular risk factors other than homocysteine, and plasma levels of folate and vitamins B6 and B12 were also considered, as was late-onset genetic risk factor APOE-epsilon4.

Exams from 1986-1990 through December 2000 revealed that 111 people had developed dementia, including 83 diagnosed with AD. Elevated homocysteine levels, defined as greater than 14 micro-mol/l, doubled the chance that a participant would develop AD, and each 5 micro-mol/l elevation increased the risk by 40%. The analysis showed that people with consistently high levels throughout the study period were at highest risk for dementia and AD. The analysis also linked elevated levels at least eight years prior to a later diagnosis of dementia and AD. The association was strong and independent of all other factors considered. No direct association was found in this study between the development of dementia and serum levels of folate and vitamins B6 and B12 in subjects.

"The good news is that we may have found a potential risk factor for AD that is modifiable,” said Neil Buckholtz, Ph.D., chief of the Dementias of Aging program at the US National Institute on Aging. "We don't know yet whether reducing homocysteine levels will reduce dementia risk, but this is something that can and will be tested in clinical trials.”




Related Links:
Boston University
Tufts University

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Aspiration System
VACUSAFE
New
Hematology Consumables
Bioblood Devices
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.